Eversept Partners LP Sells 190,164 Shares of MannKind Corporation $MNKD

Posted by Francis Steltz on Jun 18th, 2026

Eversept Partners LP lowered its stake in MannKind Corporation (NASDAQ:MNKD – Free Report) by 9.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,852,563 shares of the biopharmaceutical company’s stock after selling 190,164 shares during the quarter. Eversept Partners LP’s holdings in MannKind were worth $10,504,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of MannKind by 51.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,047,869 shares of the biopharmaceutical company’s stock valued at $10,997,000 after acquiring an additional 695,852 shares in the last quarter. Deltec Asset Management LLC increased its stake in shares of MannKind by 34.7% in the 4th quarter. Deltec Asset Management LLC now owns 974,700 shares of the biopharmaceutical company’s stock valued at $5,527,000 after acquiring an additional 251,200 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of MannKind by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 17,880,873 shares of the biopharmaceutical company’s stock valued at $101,385,000 after acquiring an additional 250,290 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in MannKind in the 4th quarter valued at $23,956,000. Finally, Apis Capital Advisors LLC acquired a new stake in MannKind in the 4th quarter valued at $6,805,000. Institutional investors own 49.55% of the company’s stock.

MannKind Trading Up 1.3%

NASDAQ MNKD opened at $3.92 on Thursday. The company has a market cap of $1.21 billion, a P/E ratio of -55.99 and a beta of 1.13. The company has a fifty day simple moving average of $3.19 and a 200 day simple moving average of $4.20. MannKind Corporation has a 12-month low of $2.23 and a 12-month high of $6.51.

MannKind (NASDAQ:MNKD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $90.17 million for the quarter, compared to analysts’ expectations of $105.38 million. MannKind had a negative return on equity of 11.21% and a negative net margin of 6.63%.MannKind’s revenue was up 15.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.04 earnings per share. Sell-side analysts predict that MannKind Corporation will post -0.06 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on MNKD shares. Zacks Research raised shares of MannKind from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Royal Bank Of Canada lifted their price target on shares of MannKind from $3.50 to $4.75 and gave the company a “sector perform” rating in a research report on Thursday, May 7th. HC Wainwright lifted their price target on shares of MannKind from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wedbush reduced their price target on shares of MannKind from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Finally, Mizuho reduced their price target on shares of MannKind from $8.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.97.

Read Our Latest Stock Analysis on MannKind

Insider Transactions at MannKind

In other MannKind news, Director Steven B. Binder sold 16,940 shares of MannKind stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $3.29, for a total transaction of $55,732.60. Following the transaction, the director directly owned 808,008 shares of the company’s stock, valued at $2,658,346.32. The trade was a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.60% of the stock is owned by corporate insiders.

MannKind Company Profile

(Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).